The Latest Breaking News from OGN

With small-cap stocks grabbing investors' attention lately, here are three discounted names with solid fundamentals to grab now, while the retracement provides a prime entry point.

Value stocks tend to perform well during economic recoveries and periods of market volatility, making them a good option for long-term investors seeking stability and growth. Additionally, these stocks often pay dividends, offering an additional income stream. Hence, fundamentally solid value stocks Enterprise Products (EPD), Energy Transfer (ET), and Organon…

The pharmaceutical industry is expected to thrive, driven by the increasing need for chronic disease management and the requirements of an aging demographic. Given the industry’s solid prospects, quality pharma stocks Organon (OGN), GoodRx Holdings (GDRX), and Collegium Pharmaceutical (COLL) could be solid buys this week. Read on….

The pharmaceutical sector is expected to grow rapidly in the coming years, owing to rising worldwide medical needs. Given the industry’s solid prospects, investors could consider buying quality pharma stocks such as Eagle Pharmaceuticals (EGRX), Organon (OGN), and Collegium Pharmaceutical (COLL) this month. Read on.

YouNeek Studios returns to Dark Horse for The Asiri Vol. 1, a new sci-fi/fantasy superhero story

Alydia Health's Jada system for postpartum hemorrhage took 11 years to reach the market; being a women's health product made its road tougher.

Despite bearish market sentiment, the healthcare industry has outperformed the broader market thanks to its defensive nature. Given overwhelming demand and the need for global healthcare development, we think the stocks of quality healthcare companies Cigna (CI), Organon (OGN), and Bristol-Myers Squibb (BMY) could be solid bets now. These stocks…

Organon & Co's (NYSE: OGN) 

Last year proved to be a record-breaking year for IPOs, amid government stimulus and soaring valuations. However, this year, the market is under pressure because of the looming interest rate hikes. Though the market could remain under pressure in the upcoming months, Wall Street analysts expect recent IPOs Organon (OGN),…